/ Eli Lilly
/ Market Analysis
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.
June 17, 2025
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
May 01, 2025
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology.
November 20, 2024
The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
July 12, 2024
LLY vs NVO: Which One is Likely to Become a $1T Company First
Tackling growing waistlines is expected to yield much shareholder value.
February 08, 2024More from The Tokenist / Eli Lilly
Pfizer’s Stock is Down 44% YTD as Woes Continue
December 01, 2023
Back to 
